A Randomised, Open-Label, Single-Dose, Single-Centre, Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of Symbicort pMDI 160/4.5µg Administered With a Spacer (With and Without Charcoal) and Symbicort pMDI 160/4.5µg Administered Without a Spacer (With and Without Charcoal).
Phase of Trial: Phase I
Latest Information Update: 07 Apr 2017
At a glance
- Drugs Budesonide/formoterol (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 31 Mar 2017 Status changed from recruiting to completed.
- 30 Nov 2016 Planned End Date changed from 1 Feb 2017 to 1 Mar 2017.
- 30 Nov 2016 Planned primary completion date changed from 1 Feb 2017 to 1 Mar 2017.